e-learning
resources
Barcelona 2010
Tuesday, 21.09.2010
Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Clinical outcomes of patients with HAP/VAP due to PVL(+) vs. PVL(-) MRSA: Results from the IMPACT-HAP study
P. Peyrani, T. Wiemken, M. Zervos, T. File, Jr., K. Ford, E. Scerpella, J. Ramirez, IMPACT-HAP Investigators (Louisville, Detroit, Aakron, New York, United States Of America)
Source:
Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients
Session:
Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients
Session type:
Thematic Poster Session
Number:
4935
Disease area:
Respiratory critical care, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Peyrani, T. Wiemken, M. Zervos, T. File, Jr., K. Ford, E. Scerpella, J. Ramirez, IMPACT-HAP Investigators (Louisville, Detroit, Aakron, New York, United States Of America). Clinical outcomes of patients with HAP/VAP due to PVL(+) vs. PVL(-) MRSA: Results from the IMPACT-HAP study. Eur Respir J 2010; 36: Suppl. 54, 4935
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Related content which might interest you:
Clinical outcomes of HIV-infected patients hospitalized with community-acquired pneumonia: Results from CAPO international cohort study
Source: Annual Congress 2010 - Risk factors and outcomes in community-acquired pneumonia
Year: 2010
Clinical cure rates in patients treated with azithromycin (AZ) for lower respiratory infections (LRTI) caused by AZ-susceptible (AZ-S) and AZ-resistant (AZ-R) organisms: Analysis of phase 3 clinical trials
Source: International Congress 2014 – Respiratory symptoms in primary care populations
Year: 2014
Site of care for community-acquired pneumonia (CAP) patients with CRB-65 score of 0-1 and pneumonia severity index (PSI) risk class (RC) of IV-V: what to do when this discrepancy occurs. Results from the CAPO international study
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
Clinical cure rates and infection types in the MOxifloxacin Treatment IV (MOTIV) study in hospitalized patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 349s
Year: 2006
Plaque-related vs. plaque-unrelated cardio and cerebrovascular events (CCVE) in hospitalized patients with community-acquired pneumonia (CAP): Preliminary results from the FAILCAP study (ClinicalTrials: NCT01143155)
Source: International Congress 2014 – Immunology of respiratory infections
Year: 2014
Performance indicators to evaluate the management of patients with ventilator-associated pneumonia: results from the IMPACT-HAP study group
Source: Annual Congress 2008 - Features of hospital-acquired pneumonia, ventilator-associated pneumonia and infection with other pathogens
Year: 2008
The presence of diabetes mellitus does not influence clinical outcomes in patient with community-acquired pneumonia: Results from the CAPO international cohort study
Source: Annual Congress 2010 - Risk factors and outcomes in community-acquired pneumonia
Year: 2010
Patients‘ characteristics do not influence duration of antibiotic therapy (ABT) in hospitalized patients with community-acquired pneumonia (CAP): results from the CAPO international study
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
The presence of diabetes does not influence clinical outcomes in patients with community-acquired pneumonia: results from the community-acquired pneumonia organization (CAPO) international cohort study
Source: Annual Congress 2007 - Severity scores and comorbidities in community-acquired pneumonia
Year: 2007
Female gender is associated with poor clinical outcomes in hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
The Spanish national clinical audit on COPD exacerbations (eCOPD). Pilot study: selection of study subjects
Source: Annual Congress 2008 - COPD in the elderly - quality of life and scores in COPD
Year: 2008
Implementation of severity guided antibiotic treatment according to Dutch guidelines in hospitalized patients with community-acquired pneumonia (CAP) included in a clinical trial
Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections
Year: 2011
Clinical, radiological and bacteriological features in geriatric tuberculosis (TB) patients (pts) - initial treatment and outcome
Source: Eur Respir J 2002; 20: Suppl. 38, 363s
Year: 2002
Thrombocytosis predicts poor outcomes in patients with community-acquired pneumonia: results from the CAPO international cohort study
Source: Annual Congress 2008 - Diagnostic tests in lower respiratory tract infections
Year: 2008
Epidemiology and outcomes in hospitalized patients with health-care-associated pneumonia (HCAP) and community-acquired pneummonia (CAP)~ A prospective observational cohort analysis
Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia
Year: 2009
COPD-specific co-morbidity test (COTE) for predicting mortality in COPD – Results of an European, multicenter study
Source: International Congress 2014 – Markers
Year: 2014
Real-world effects of lumacaftor/ivacaftor (LUM/IVA) in people with cystic fibrosis (pwCF): interim results of a long-term safety study using US CF Foundation Patient Registry (CFFPR) data
Source: Virtual Congress 2021 – Clinical effects of CFTR modulatory therapy and lung inflammation in children with cystic fibrosis
Year: 2021
Real-world effects of tezacaftor/ivacaftor (TEZ/IVA) in people with cystic fibrosis (pwCF): interim results of a long-term safety study using US CF Foundation Patient Registry (CFFPR) data
Source: Virtual Congress 2021 – Clinical effects of CFTR modulatory therapy and lung inflammation in children with cystic fibrosis
Year: 2021
Effectiveness of azithromycin (AZ) in patients with community-acquired pneumonia (CAP): an evidenced-based meta-analysis of randomized controlled trials (RCTs)
Source: Eur Respir J 2001; 18: Suppl. 33, 137s
Year: 2001
Mortality directly related to community-acquired pneumonia (CAP) in hospitalized patients: results from the community-acquired pneumonia organization (CAPO) international cohort study
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept